H.R. 2700: Lowering Prescription Drug Costs and Extending Community Health Centers and Other Public Health Priorities Act

Before you vote › Federal bills

H.R. 2700: Lowering Prescription Drug Costs and Extending Community Health Centers and Other Public Health Priorities Act

116th Congress · introduced 2019-05-14 · Health · Latest: Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.

federal

Save to my notebook What does this mean? Print

Official title

Lowering Prescription Drug Costs and Extending Community Health Centers and Other Public Health Priorities Act

Plain summary

Lowering Prescription Drug Costs and Extending Community Health Centers and Other Public Health Priorities Act This bill addresses prescription drugs and extends several health care, research, and workforce programs. Currently, a generic drug manufacturer is awarded 180 days of exclusivity on the market if it is the first applicant to file an application with the Food and Drug Administration (FDA), and the exclusivity period begins upon the first applicant's commercial marketing. The bill authorizes the FDAto approve a subsequent generic drug application prior to the first applicant's first date of commercial marketing if certain conditions are met. The bill prohibits a brand-name, generic, or biosimilar drug manufacturer from entering into certain agreements to resolve or settle a patent infringement claim in connection with the sale of a drug or biological product. Such an agreement, with specified exclusions, is a violation of the bill if the filer of the subsequent generic application receives something of value and agrees to limit or forego research, development, manufacturing, marketing, or sales of the generic drug or biological product. The developer of a drug or biological product, such as a generic or biosimilar version of a drug, may bring a civil action against the license holder of an approved drug if the holder has declined to make available sufficient quantities of the approved drug for the developer's testing. The bill also extends several health care, research, and workforce programs, including the National Health Service Corps, through FY2020.

Congressional Research Service summary (Introduced in House), quoted unchanged (nonpartisan). Read the source.

What a vote does

PSI Sci description of the legislative step (not an opinion).

The strongest published arguments

Alternatives

Needs sources: no published alternatives yet (for example a different bill, a law instead of an amendment, or keeping current law). We only show items backed by a published source. Suggest one.

How did my representative vote? · This bill's floor votes

Officials and money

Sponsor: Rep. Burgess, Michael C. [R-TX-26] · 44 cosponsors

Cost estimate: No cost estimate published yet.

Cosponsors on this site

Earl L. "Buddy" Carter (R-GA), Gus M. Bilirakis (R-FL), Richard Hudson (R-NC), Tim Walberg (R-MI), Brett Guthrie (R-KY), H. Morgan Griffith (R-VA), Robert E. Latta (R-OH), Steve Scalise (R-LA), J. French Hill (R-AR), Roger Marshall (R-KS), Elise M. Stefanik (R-NY), Barry Loudermilk (R-GA), Mario Diaz-Balart (R-FL), Robert J. Wittman (R-VA), Mike Bost (R-IL), David P. Joyce (R-OH), Mark E. Amodei (R-NV), Ann Wagner (R-MO)

No linked floor roll calls in our collected records yet. This does not mean the bill has never had a vote. Check the official bill history.

Sources

• Congressional Research Service summary (Introduced in House)
• Congress.gov
• Data: GovInfo BILLSTATUS bulk data (Library of Congress), BILLSTATUS-116hr2700.xml <https://www.govinfo.gov/bulkdata/BILLSTATUS/116/hr>

Record fed-us-cong116-hr2700 · catalog fed-us-congress-bills-cong116 · updated 2026-11-15 by psicol fed-bills-cong116